Key facts
- Gaudi Clinical’s last known valuation is $21.9M (Feb 2025).
- It has raised $11.4M; the latest was Early Stage VC ($8.9M) in Feb 2025.
- Notable investors include Mizuho Capital, JIC Venture Growth Investments, Shizuoka Capital, Samurai Incubate, Jafco — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Gaudi Clinical
- ·The full record, as it builds
Funding rounds
No funding rounds for Gaudi Clinical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gaudi Clinical
Developer of cutting-edge regenerative medicine platform intended for patients. The company support research and development in a wide range of fields that utilizes the potential of a comprehensive health university, from the development of new medical technologies based on clinical needs and data-driven research and development to healthcare research and development that combines sports and health sciences, enabling users to get a one-stop support for social implementation of development seeds.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2021
- Website
- gaudi-clinical.co.jp/
- Ownership
- Privately Held (backing)
Gaudi Clinical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gaudi Clinical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gaudi Clinical in its N-PORT filings yet. We sweep new filings monthly.